Computed tomography calcium scoring association and reclassification of clinical cardiovascular risk in asymptomatic Mexican patients by Vázquez Mézquita, Aldo Javier et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Computed tomography calcium scoring association and
reclassification of clinical cardiovascular risk in asymptomatic
Mexican patients
Citation for published version:
Vázquez Mézquita, AJ, Williams, MC, Choza Chenhalls, R, Guzmán Martínez, NB, Chischistz Condey, AP,
Acosta Falomir, MJ, Téliz Meneses, MA & Vázquez Sánchez, MN 2020, 'Computed tomography calcium
scoring association and reclassification of clinical cardiovascular risk in asymptomatic Mexican patients',
SAGE Open Medicine, vol. 8, pp. 205031212093823. https://doi.org/10.1177/2050312120938233
Digital Object Identifier (DOI):
10.1177/2050312120938233
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
SAGE Open Medicine
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 31. Jul. 2020
https://doi.org/10.1177/2050312120938233
SAGE Open Medicine
Creative Commons CC BY: This article is distributed under the terms of the Creative Commons Attribution 4.0 License  
(https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of  
the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages  
(https://us.sagepub.com/en-us/nam/open-access-at-sage).
SAGE Open Medicine
Volume 8: 1 –9
© The Author(s) 2020
Article reuse guidelines: 
sagepub.com/journals-permissions
DOI: 10.1 77/205 3121209382
journals.sagepub.com/home/smo
Computed tomography calcium scoring 
association and reclassification of clinical 
cardiovascular risk in asymptomatic  
Mexican patients
Aldo Javier Vázquez Mézquita1,2 , Michelle Claire Williams1,  
Rafael Choza Chenhalls3, Nancy Berenice Guzmán Martínez2,  
Ana Patricia Chischistz Condey2, Maria José Acosta Falomir2,  
Marco Antonio Téliz Meneses2 and María Nayeli Vázquez Sánchez2
Abstract
Objectives: To establish tailored preventive treatment, we studied the ability of coronary artery calcium scoring to reclassify 
patients with intermediate cardiovascular risk and its association with additional risk factors in our Mexican preventive care 
center.
Materials and methods: In this retrospective cohort study, we analyzed 520 asymptomatic patients from a Mexican primary 
prevention population between 2014 and 2018. Coronary artery calcium scoring, laboratory results, and anthropometric 
measurements (abdominal circumference and body mass index) were assessed. The Framingham risk score and American 
Heart Association/American College of Cardiology (AHA/ACC) atherosclerotic cardiovascular disease risk algorithm were 
calculated. Correlations between coronary artery calcium scoring, anthropometric measurements, and clinical cardiovascular 
risk scores were assessed. We assessed the ability of coronary artery calcium scoring to reclassify patients recommended 
for statin therapy compared with the cardiovascular risk scores.
Results: Patients had a mean age of 67.5 years (SD ± 9.8) and 294 subjects (56.5%) were male. Coronary artery calcium 
scoring has a positive correlation with age, AHA/ACC atherosclerotic cardiovascular disease risk algorithm, and Framingham 
risk score (p < 0.001 for all). Coronary artery calcium scoring was prevalent, occurring in 63.2% of patients with a median 
Agatston score of 22 with and interquartile range of 178. Male gender, older age, smoking habit, diabetes, and abdominal 
circumference were independent predictors of coronary artery calcium scoring (p < 0.001). Coronary artery calcium scoring 
downwardly reclassified 44.9% of patients in intermediate cardiovascular risk categories by the AHA/ACC atherosclerotic 
cardiovascular disease risk algorithm and 43.9% by the Framingham risk score. Coronary artery calcium scoring upwardly 
reclassified 46.8% of patients in intermediate risk categories by the AHA/ACC atherosclerotic cardiovascular disease risk 
algorithm and 56% by the Framingham risk score.
Conclusion: Coronary artery calcium scoring is prevalent in this Mexican primary prevention cohort and has the ability to 
reclassify a significant percentage of intermediate cardiovascular risk patients.
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Introduction
Coronary artery disease (CAD) remains a leading cause of 
death around the globe. Approximately, 17.5 million people 
died because of cardiovascular disease in 2012, which rep-
resented 30% of the total mortality worldwide, of which 
approximately, 7.4 million of these deaths were caused by 
CAD.1 Countries with low- and medium-income levels are 
the most affected in regions like Latin America, the 
Caribbean, Central and Eastern Europe, as well as Central 
Asia.2 In 2015, the death rate secondary to ischemic heart 
disease was higher in Central Latin America (119 per 100, 
000) and Central Asia (336 per 100,000) compared with 
Western Europe (80 per 100, 000) and North America (106 
per 100,000).2,3
To identify asymptomatic patients with CAD, we cur-
rently rely on clinical tools and cardiovascular risk scores, 
such as the Framingham risk score (FRS).4 Furthermore, 
they often include a limited diversity, including low numbers 
of women and ethnic or racial groups. Clinical parameters 
that may be used to assess cardiovascular risk include the 
assessment of visceral fat. However, limited information is 
available on how clinical assessment of visceral fat varies 
between populations of different ethnicities.5,6
Non-invasive imaging with computed tomography (CT) 
coronary artery calcium scoring (CACS) can be used to iden-
tify and quantify atherosclerotic plaque burden. This can be 
applied to identify CAD in patients who traditional risk scor-
ing systems may miss, and who may benefit from preventive 
medication and lifestyle modification advice. This has 
important health economic implications.7,8 Previous studies 
have shown that CACS can reclassify patients compared 
with other scoring systems, such as the FRS9 or the athero-
sclerotic cardiovascular disease (ASCVD) risk algorithm by 
the American Heart Association (AHA) and the American 
College of Cardiology (ACC).10–13
In the Mexican population, a previous study by Posadas-
Romero et al.,14 identified the prevalence of coronary artery 
calcified plaques in individuals between 34 and 75 years of 
age, 40% was for men and 14% for women. In the Multiethnic 
Study of Atherosclerosis (MESA), the prevalence of coro-
nary artery calcified plaques in the Hispanic population was 
57.5% in men and 35% in women.14 This overestimation of 
cardiovascular risk has been reported in other racial and eth-
nic groups.11
Even though, many studies that determine the association 
between cardiovascular risk and CACS have been performed 
in other countries, we currently do not have studies in Mexico 
that assess how many patients could be reclassified by CACS 
in other cardiovascular risk categories.
The purpose of detecting subjects at an intermediate or 
high cardiovascular risk is imperative for us to establish tai-
lored preventive treatment, if necessary. We, therefore, ana-
lyzed a possible correlation between CACS, anthropometric 
measurements, and both cardiovascular risk scores (FRS and 
the AHA/ACC ASCVD risk algorithm) as a main objective. 
As a primary hypothesis, we considered that CACS has a 
positive correlation with anthropometric measurements and 
both cardiovascular risk scores.
Methods and materials
Study population
This was a single institution retrospective cohort study that 
included patients representing a middle- to high-income 
adult asymptomatic population in Mexico City and its 
surrounding metropolitan area. These are asymptomatic 
patients who self-refer to our preventive care unit in which 
CACS CT is offered to them. Ethical approval by the 
Research and Ethics Committee was obtained before the 
study began (ID number ABC 18-11); patients from our 
database were contacted and a written consent was obtained 
from them to use their data for this study. We included all 
asymptomatic male and female patients born in Mexico, 
who had imaging, clinical and laboratory information 
obtained on the same day in our institution. Exclusion cri-
teria were the presence of previous vascular or cardiac 
interventional procedures and symptoms of CAD. Patients 
whose age or laboratory values could not be processed by 
the cardiovascular risk calculators or were incomplete 
(FRS and the AHA/ ACC ASCVD risk algorithm) were 
eliminated from the analysis.
Assessment of cardiovascular risk factors
Data for each patient were obtained from their clinical 
records, including the age, gender, high-density lipoprotein 
(HDL) and low-density lipoprotein (LDL) levels, blood 
pressure levels, body mass index (BMI), abdominal circum-
ference, smoking habit, diabetes mellitus, and systemic arte-
rial hypertension, the latter previously diagnosed by their 
physicians.
Assessment of cardiovascular risk scores
Clinical and laboratory data were used to calculate the FRS 
and AHA/ACC ASCVD score to determine each patient’s 
cardiovascular risk (%) for the next 10 years.9–11 Both calcu-
lators used age, gender, ethnicity, HDL and LDL levels, 
blood pressure level, diabetes mellitus, systemic hyperten-
sion, and smoking habit as parameters. Four radiology resi-
dents (A.J.V.-M, N.B.G-M, M.J.A.-F, and A.P.C-C) collected 
the information stored in each patient’s file and used it to 
calculate the cardiovascular risk scores with the aforemen-
tioned calculators.
Regarding the AHA/ACC ASCVD risk algorithm, statin 
therapy is not recommended in patients with a low-risk score 
(<5%), while in patients with an intermediate risk score 
(5%–7.5%), statins can be considered. In patients with an 
intermediate (7.5%–20%) or high-risk score (>20%), statin 
therapy is recommended.12
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Regarding the FRS, statin therapy is not recommended in 
patients with a low cardiovascular risk (<10%). In contrast, 
statin therapy is recommended in patients with an intermedi-
ate (10%–20%) or high (>20%) cardiovascular risk.9
Imaging technique and interpretation
Non-contrast electrocardiogram-gated CT of the heart was 
performed to assess CACS using a Philips Brilliance 64-slice 
CT scanner. Each slice has a 3 mm increment, tube voltage of 
120 kVs, the effective dose was calculated by multiplying 
the dose length product (DLP) and a w conversion coeffi-
cient of 0.014. The approximate effective dose was 0.85 mSv. 
The official calcium scoring studies were interpreted by two 
radiologists specialized in cardiovascular imaging and two 
cardiologists specialized in cardiovascular imaging. The four 
specialists were not part of this protocol and were blinded 
from the clinical and laboratory data.
Coronary artery calcium score
For the calcium scoring analysis, we used the Agatston 
score method15 to quantify coronary artery plaque calcifica-
tion, which is based on detecting voxels with a value equal 
to or higher than 130 Hounsfield units. The result was clas-
sified using the Coronary Artery Calcium Data and 
Reporting System (CAC-DRS) categories published by the 
Society of Cardiovascular Computed Tomography:16 very 
low cardiovascular risk for a CACS of 0 (CAC-DRS 0), 
mildly increased cardiovascular risk for CACS between 1 
and 99 (CAC-DRS 1), mildly to moderately increased car-
diovascular risk for CACS between 100 and 299 (CAC-
DRS 2), and moderately to severely increased cardiovascular 
risk for CACS equal to or higher than 300 (CAC-DRS 3). 
The score values used in this study were acquired from the 
official reports.
Sample calculation
Our population was divided into gender (male or female). 
The average sensibility of CACS to detect calcified plaques 
is 90%. Regarding the prevalence of CAD in the Mexican 
population, a study by Posadas-Romero et al.14 indicated that 
men have a prevalence of around 40%, while women have a 
prevalence of 14%. Based on these data, the minimum num-
ber of male subjects required was 75, while the minimum 
number of female subjects needed was 215, considering an 
alpha value of 0.05, a power of 0.8. We decided to use the 
sample calculation based on the epidemiological data by 
Posadas-Romero et al.,14 which is explicitly based on the 
Mexican population.
Statistical analysis and software processing
Statistical analysis was performed using SPSS Statistics (ver-
sion 25 by IBM®). Normal distributed variables are presented 
in means and standard deviations, whereas, non-normally 
distributed variables are presented as medians and percen-
tiles. The statistical significance was assessed using the t-test 
for independent variables, the Mann–Whitney U, chi-square, 
Kruskal–Wallis, Wilcoxon, Spearman’s rho, and multivariate 
regression tests as appropriate. A two-tailed p-value < 0.05 
was considered statistically significant.
Results
A total of 640 patients were found in our database, who 
were screened at our preventive care unit over 4 years 
(2014–2018). Of these, 579 consented to inclusion in this 
study. Forty-three were excluded because of chest pain 
symptoms at the time of assessment. A total of 16 patients 
were excluded because of previous cardiovascular proce-
dures, such as coronary stents. A total of 520 asymptomatic 
patients with complete data were included, the majority 
were men with a total of 294 subjects (56.5%) with a mean 
age of 67.5 years (SD ± 9.8; Table 1). In the cardiovascular 
risk score stratification, 459 patients could be classified 
using the AHA/ACC ASCVD risk algorithm and 401 
patients with the FRS.
Coronary artery calcification was present in 63.2% (329) 
of patients with a median Agatston score of 22 (Table 1). The 
CAC-DRS category distribution by gender is illustrated in 
Figure 1.
CACS correlation with cardiovascular risk scores 
and anthropometric measures
Overall, CACS and abdominal circumference indicated a 
low but positive correlation of 0.235 (p < 0.001). In the case 
of BMI, CACS had an overall low correlation coefficient of 
0.134 (p < 0.01). Age and CACS indicated a correlation 
coefficient of 0.416 (p < 0.0001). Regarding cardiovascular 
risk scores, CACS and the AHA/ACC ASCVD risk algo-
rithm had an overall correlation coefficient of 0.436 
(p < 0.001). Meanwhile, CACS and the FRS had an overall 
positive correlation of 0.430 (p < 0.001). The correlation 
coefficient values for each gender are listed in Table 2.
Coronary calcified plaque burden predictors
A multivariate regression analysis was performed, which 
determined that increased age, male gender, as well as diabe-
tes mellitus and abdominal circumference are independent 
predictors for calcified plaque burden. However, BMI, sys-
temic arterial hypertension, and a smoking habit were not 
independent risk predictors for calcified plaque burden. The 
results of the multivariate regression analysis are presented 
in Table 3.
Comparison between CACS and AHA/ACC ASCVD risk categories. 
For the 459 subjects where the AHA/ACC ASCVD risk 
algorithm could be assessed, 65 (14.1%) patients were 
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classified in the “statin not recommended” group, 207 (45%) 
patients in the “consider statin” group, and 187 (40.7%) in 
the “statin recommended” group. In contrast, with the influ-
ence of CACS, 158 (34.4%) patients were classified in the 
“statin not recommended” group and 284 (61.8%) in the 
“statin recommended” group. Only 17 (3.7%) patients stayed 
in the “consider statin” group. Overall, CACS reclassified 
patients in the intermediate cardiovascular risk categories, 
with 44.92% downward and 46.86% upward. The frequen-
cies for each gender are listed in Table 4. There was a statisti-
cally significant difference between the distributions of the 
AHA/ACC ASCVD risk estimate with and without the 
CACS reclassification (p < 0.001), the values are listed in 
Table 5. In Figure 2, we present six examples of statin drug 
therapy recommendations determined by the AHA/ACC 
ASCVD risk algorithm and CACS.
Table 1. Demographic information.
Overall Male Female *p-value
Number of patients 520 294 226  
Age (years), mean ± SD 67.8 ± 9.5 67.5 ± 9.8 68 ± 9.2 0.089
Agatston calcium score, median 
(25th; 75th percentiles)
22 (0; 178) 50 (0; 267) 2 (0; 98.12) <0.001
CAC-DRS, n (%) CAC-DRS 0 191 (36.8) 83 (28.2) 108 (47.8) <0.001
 CAC-DRS 1 152 (29.2) 89 (30.3) 63 (27.9)  
 CAC-DRS 2 83 (16) 51 (17.3) 32 (14.2)  
 CAC-DRS 3 94 (18) 71 (24.1) 23 (10.2)  
CACS > 0 329 (63.2) 211 (71.7) 118 (52.2)  
BMI mean ± SD 26.4 ± 4.3 26.6 ± 3.8 26.1 ± 4.8 0.158
Abdominal circumference (cm), 
mean ± SD
92 ± 11.8 96.5 ± 9.8 87 ± 12.1 <0.001
ACC/AHA ASCVD risk algorithm, 
median (25th; 75th percentiles)
16.6 (9; 27) 20.4 (12.6; 29.8) 13.4 (6.3; 22.4) <0.001
FRS, median (25th; 75th percentiles) 19.8 (10.2; 31.9) 25 (16; 38.9) 12.7 (7.4; 21.6) <0.001
Diabetes mellitus, n (%) 72 (13.8) 39 (13.3) 33 (14.6) 0.633
Systemic arterial hypertension, n (%) 197 (37.8%) 114 (38.8%) 83 (36.7%) 0.633
Smoking status, n (%) 214 (41.2%) 128 (43.5%) 86 (38.1%) 0.208
CAC-DRS: Coronary Artery Calcium Data and Reporting System; CACS: coronary artery calcium scoring; ACC: American College of Cardiology;  
AHA: American Heart Association; ASCVD: atherosclerotic cardiovascular disease; FRS: Framingham risk score; BMI: body mass index. *A p-value < 0.05 
shows a statistically significant difference in the frequencies between the male and female groups.
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Figure 1. CAC-DRS frequencies determined by gender.
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Comparison between CACS and Framingham risk 
categories
Considering the whole sample of 401 subjects by the FRS 
without the influence of CACS, 96 (23.9%) were classified 
in the low-risk category, 107 (26.6%) in the intermediate risk 
category, and 198 (49.3%) in the high-risk category.
Regarding the FRS, 96 patients (23.9%) were included in 
the “statin not recommended” group and 305 patients (76.1%) 
were included in the “statin recommended” group. In con-
trast, with the influence of CACS, a total of 143 patients 
(35.66%) were included in the “statin not recommended” 
group, whereas 258 patients (64.4%) were included in the 
“statin recommended” group. Overall, CACS reclassified 
Table 2. CACS correlation coefficients with anthropometric measures and cardiovascular risk scores.
Overall *p-value Female *p-value Male *p-value
Age 0.416 <0.001 0.43 <0.001 0.42 <0.001
Abdominal circumference 0.235 <0.001 0.284 <0.001 0.05 0.393
BMI 0.134 <0.01 0.204 <0.01 0.038 0.522
AHA/ACC ASCVD risk algorithm 0.436 <0.001 0.407 <0.001 0.36 <0.001
FRS 0.43 <0.001 0.379 <0.001 0.334 <0.001
AHA: American Heart Association; ACC: American College of Cardiology; ASCVD: atherosclerotic cardiovascular disease; CACS: coronary artery 
calcium scoring; FRS: Framingham risk score; BMI: body mass index.
*p-values < 0.05 were considered statistically significant.
Table 3. Multivariate regression analysis assessing predictors of CACS > 0. The p-values < 0.05 were considered statistically significant.
CAC > 0 b-value Standard 
error
p-value Odds 
ratio
95% confidence interval
Lower bound Upper bound
Age 0.103 0.013 0.000 1.109 1.080 1.138
BMI –0.058 0.047 0.215 0.944 0.861 1.034
Abdominal circumference –0.278 0.277 0.025 1.042 1.005 1.081
Male gender 0.748 0.255 0.003 2.113 1.281 3.486
Smoking habit 0.170 0.217 0.434 1.185 0.774 1.814
Previous diagnosis of diabetes mellitus 0.875 0.358 0.014 2.400 1.191 4.837
Previous diagnosis of systemic arterial hypertension 0.134 0.224 0.551 1.143 0.736 1.775
CACS: coronary artery calcium scoring; CAC: coronary artery calcium; BMI: body mass index.
Table 4. Statin recommendation based on CACS and cardiovascular risk based on the AHA/ACC ASCVD and FRSs.
Overall (%) p-value* Female (%) p-value* Male (%) p-value*
AHA/ACC ASCVD 
risk algorithm
Total sample (n) 459 (100) 203 (44.2) 256 (55.8)  
Statin not 
recommended
Without CACS 65 (14) < 0.001 37 (57) < 0.001 28 (43) < 0.001
CACS considered 158 (34) 100 (63.3) 58 (36.7)  
Consider statin Without CACS 37 (8) < 0.001 26 (70.3) 0.002 11 (29.7) 0.008
CACS considered 17 (4) 10 (58.8) 7 (41.2)  
Statin recommended Without CACS 357 (78) < 0.001 140 (39.2) < 0.001 217 (60.8) < 0.001
CACS considered 284 (62) 93 (32.7) 191 (67.3)  
FRS Total sample (n) 401 178 (44.4) 223 (55.6)  
Statin not 
recommended
Without CACS 96 (24) < 0.001 67 (69.8) < 0.001 29 (30.2) < 0.001
CACS considered 143 (36) 99 (69.2) 44 (30.8)  
Statin recommended Without CACS 305 (76) < 0.001 111 (36.4) < 0.001 194 (63.6) < 0.001
CACS considered 258 (64) 79 (30.6) 179 (69.4)  
CACS: coronary artery calcium scoring; AHA: American Heart Association; ACC: American College of Cardiology; ASCVD: atherosclerotic cardiovascu-
lar disease; FRS: Framingham risk score.
Values show number (%). 
*p-values < 0.05 demonstrate a statistically significant difference in the frequencies for each statin recommendation with and without the influence of CACS.
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patients in the intermediate cardiovascular risk category, with 
43.9% downward and 56.1% upward. The frequencies for 
each gender are listed in Table 4. There was a statistically 
significant difference between the groups with and without 
the influence of CACS (p < 0.001), the values are listed in 
Table 6.
Discussion
We have shown that coronary artery calcification is frequent 
in our primary prevention cohort and that its presence or 
absence can reclassify patients based on both the FRS and 
AHA/ACC ASCVD risk score. CACS reclassified most of 
the patients with intermediate cardiovascular risk into lower 
or higher categories of both the FRS and AHA/ACC ASCVD 
risk score. Older age, male gender, smoking habit, as well as 
a previous diagnosis of diabetes mellitus, and abdominal cir-
cumference were independent risk predictors of coronary 
calcified plaque burden.
Greenland et al.12 recommended CACS as a tool to reclas-
sify cardiovascular risk compared with the AHA/ACC 
ASCVD risk algorithm.17–19 As an imaging tool that can be 
used to tailor patient treatment, CACS may reduce costs for 
hospitals and patients alike.7,8 Considering both cardiovascu-
lar risk scores, around 44% of patients with intermediate car-
diovascular risk were reclassified downwards because of a 
CAC score of zero, which would indicate that they do not 
need statin therapy. In contrast, around 51% of patients in the 
intermediate risk category had a stronger recommendation to 
start statin therapy because of a CAC score > 0. The high 
number of reclassified patients in the intermediate group in 
our study could be due to the high proportion of male patients. 
Male patients had higher median CAC score compared with 
female patients, and thus were more frequently reclassified. 
Most of the patients with intermediate cardiovascular risk 
who were not reclassified were women and had a CACS less 
than 100. It is important to note that a CAC score of zero is 
correlated with a low mortality rate.19
In this study, we had a positive correlation between CACS 
and cardiovascular risk assessment tools (AHA/ACC 
ASCVD and Framingham). We were able to identify older 
age, male gender, as well as a previous diagnosis of diabetes 
mellitus and abdominal circumference as independent pre-
dictors for the presence of calcified coronary plaques, simi-
lar to previous studies.5,6,9,19 Smoking was more common in 
the male population than the female population. Nonetheless, 
both were significantly higher than the national prevalence 
of 8.7% in females and 27.1% in males reported in the last 
national Mexican addiction survey ENCODAT 2016–2017.20 
The BMI of both male and female groups was similar 
(BMI = 26), which is slightly above the upper cut-off point 
for the “normal” category.21 In the case of abdominal cir-
cumference, the mean of both genders was above the upper 
limit of the “normal” category.22 The percentage of patients 
with diabetes mellitus (13–14%) is similar to the prevalence 
reported in the Mexican population.23 More than a third of 
the included patients had a previous diagnosis of systemic 
arterial hypertension, which is also similar to the prevalence 
reported in our country.24
Regarding CACS and BMI, we did find a positive corre-
lation between these variables in the female population. 
Nonetheless, this was not the case in the male and overall 
groups. In our study, BMI was not identified as a predictor for 
calcified plaque burden. Oh et al.6 tried to identify a relationship 
between waist–height ratio and CACS progression over 4 years 
and found an increased calcified plaque burden in patients with 
Table 5. Statin recommendation based on CAC-DRS and ASCVD risk estimate.
Statin recommendation based on CAC-DRS and ASCVD risk estimate Total
Gender ASCVD risk 
estimate
CAC-DRS
Very low Mildly  
increased
Moderately  
increased
Moderately to 
severely increased
Female < 5% 27 8 2 0 37
 5–7.5% 16 (–) 9 0 1 26
 7.5–20% 47 (–) 19 (+) 11 (+) 6 (+) 83
 > 20% 15 19 16 7 57
Male < 5% 23 5 0 0 28
 5–7.5% 4 (–) 5 1 1 11
 7.5–20% 26 (–) 25 (+) 20 (+) 16 (+) 87
 > 20% 27 40 24 39 130
Total 185 130 74 70 459
Very low = CAC-DRS 0; mildly increased = CAC-DRS 1; moderately increased = CAC-DRS 2; moderately to severely increased = CAC-DRS 3. Blue = statin 
not recommended; yellow = consider for statin; orange = recommend statin. (–) = CAC can reclassify risk downwardly; (+) = CAC can reclassify risk 
upwardly. CAC-DRS: Coronary Artery Calcium Data and Reporting System; ASCVD: atherosclerotic cardiovascular disease.
There was a statistically significant difference between the distributions of the AHA/ACC ASCVD risk estimate with and without the CACS reclassification 
(p < 0.001).
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high waist–height ratios. In our study, we measured abdominal 
circumference as a secondary marker of central obesity and 
determined that it is an independent risk predictor for calcified 
plaque burden, with a positive correlation in female patients; the 
latter was not the case in male patients. Although both studies 
measure different variables, both attempt to link central obesity 
and calcified coronary plaques.
In the study by Alashi et al.,25 41% of asymptomatic 
patients in the Cleveland Clinic were reclassified using the 
ASCVD risk algorithm in lower or higher cardiovascular 
risk categories because of CACS. In comparison, our study 
was able to reclassify 190 patients, which corresponds to 
36% of our sample. This result may suggest that Mexican 
patients form middle- to high-income groups cannot be 
equally reclassified as in developed countries, such as the 
United States, even though our subjects come from groups 
with an allegedly healthier lifestyle than the rest of the 
Mexican population.
It is important to mention that our study is valuable to our 
population, because we lacked information regarding how 
many patients in Mexico could be reclassified in their cardi-
ovascular risk category by the influence of CACS. Normally, 
we base our clinical approaches in studies made in other 
populations, therefore, it is imperative to us to know how 
CACS could be used in a setting like ours.
Limitations
Our study’s population does not represent the complete eth-
nic and economic groups found in the Mexican territory. 
Importantly, this population is part of the medium- and high-
income classes of our society. Belonging to the low-income 
class has been considered a risk factor for CAD in the previ-
ous literature.24 In addition, downstream investigation, medi-
cation use, and subsequent outcomes are not available. We 
recommend future studies regarding the reclassification of 
Figure 2. Patients classified by the AHA/ASCVD risk algorithm and CAC-DRS. (a) A 75-year-old female patient with a cardiovascular 
risk of 39% and CAC-DRS 0; in this case, statin drug therapy is recommended, regardless of CACS. (b) A 65-year-old female with a 
cardiovascular risk of 3.9% and CAC-DRS 1; upwardly reclassified with a statin drug therapy recommendation. (c) A 75-year-old female 
with a cardiovascular risk of 5.7% and CAC-DRS 3; upwardly reclassified with a statin drug therapy recommendation. (d) A 75-year-old 
male with a cardiovascular risk of 33.5% and CAC-DRS 3; this patient stayed in the high-risk category.
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cardiovascular risk by CACS in the low-income Mexican 
population, which may behave quite different from the popu-
lation we studied. It is important to remember that cardiovas-
cular risk by CACS may reduce unnecessary statin drug use 
therapy, which can become a constant and unbearable 
expense for people with low income. Moreover, it would 
avoid unnecessary drug side effects. Nonetheless, because of 
the smaller proportion of reclassified patients in our study, in 
comparison with the Alashi study in the United States, it is 
important to determine the proportion of patients of low-
income population in Mexico that could be reclassified by 
the same method.
Importantly, it must be remembered that the absence of 
calcified coronary plaques does not exclude the presence of 
obstructive coronary artery stenoses or adverse plaque 
characteristics.25
In this study, we did not determine whether CACS is cost-
effective as a preventive tool to establish a tailored statin 
therapy, as suggested by other literature.7,8 In our case, the 
annual medical checkups were paid for by the patients or 
their insurance companies. Therefore, we cannot establish 
the cost-effectiveness at a national healthcare level.
We currently do not know whether this reclassification 
allows for an increased accuracy in risk prediction, since 
no survival data are available. Therefore, we recommend 
a follow-up study over the next decade in order by meas-
uring the event rate of coronary ischemic disease and 
myocardial infarction to determine the accuracy of this 
method.
Conclusion
CACS is prevalent in our Mexican primary prevention popu-
lation and reclassified the majority of patients in intermediate 
cardiovascular risk groups using both the AHA/ACC ASCVD 
and FRS. The reclassification by CACS offers a tailored 
preventive approach for asymptomatic patients, which could 
reduce healthcare costs and unnecessary drug side effects and 
identify patients who may be missed by risk scoring systems. 
Anthropometric measurements were only associated with 
calcified plaque burden in female patients.
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